Best adjuvant (assist) for chemotherapy | 1+1>487% |
Effectively improve chemotherapy effect, treatment, immunity.
Reduce side effects and recurrence.
Overview / Relation / Abstract / Role / Principle / Action / Mechanism / Function / Work |
Neuroendocrine Tumors: Latest Research
Abstract / Summary / Overview of Apoptosis.
Why do cells undergo apoptosis?
The relationship between cancer cells and apoptosis.
Where are the weaknesses and symptoms of cancer cells?
Are cancer cells aggressive?
Extraordinary Solamargine (Role, Principle, Action, Mechanism, Function, Work)
Solamargine's major function mechanism:
Solamargine vs cancer
Best Chemotherapy Adjuvant. (1+1>478%)
Effectively improve chemotherapy effect and cure.
When cancer cells are less resistant to drugs, chemotherapy becomes more effective.
Extract : https://www.cancer.net/cancer-types/
Neuroendocrine Tumors: Latest Research
You will read about the scientific research being done to learn more about neuroendocrine tumors (NETs) and how to treat them.
Doctors are working to learn more about NETs, ways to prevent them, how to best treat them, and how to provide the best care to people diagnosed with this type of tumor. The following areas of research may include new options for patients through clinical trials. Always talk with your doctor about the best diagnostic and treatment options for you.
Immunotherapy. As described in Types of Treatment, immunotherapy uses the body's natural defenses to fight cancer by improving your immune system’s ability to attack cancer cells. Researchers are testing new cancer vaccines on NETs. Another specific area of immunotherapy research is looking at drugs that block a protein called PD-1. PD-1 is found on the surface of T cells, which are a type of white blood cell that helps the body’s immune system fight disease. PD-1 stops the immune system from destroying tumor cells, so stopping PD-1 from working allows the immune system to better eliminate the disease.
The U.S. Food and Drug Administration (FDA) has approved a PD-L1 inhibitor, atezolizumab (Tecentriq), in combination with carboplatin and etoposide chemotherapy (both available as generic drugs) for the treatment of metastatic small cell lung cancer. NETs of the lung are a very different disease, but the effectiveness of atezolizumab shows the need to study immunotherapy specifically in those with a lung NET.
Also, chimeric antigen receptor (CAR) T-cell therapy combined with antibody-drug conjugates, a type of targeted therapy, is being explored. In CAR T-cell therapy, some T cells are removed from a patient’s blood. Then, the cells are changed so they have specific proteins called receptors. The receptors allow the changed T cells to recognize the cancer cells. The changed T cells are then returned to the patient’s body. Once there, they seek out and destroy cancer cells. Learn more about the basics of CAR T-cell therapy.
Targeted therapy and combined treatments. As noted in Types of Treatment, research continues on targeted therapy. Monoclonal antibodies are a type of targeted therapy that blocks tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help destroy them or carry tumor-destroying substances to them.
Chemotherapy. Because NETs have unique properties that healthy cells do not, researchers are trying to develop “smart” chemotherapy that only attacks tumor cells and not all cells.
Genetics. As described in Risk Factors, family history of MEN1 may play a role in an individual’s risk for developing a NET. Researchers are investigating MEN1 to learn more about this and other hereditary risk factors, as well as the role mutations, or changes, in genes plays in NETs.
Peptide receptor radionuclide therapy (PRRT). Research is underway on how to improve PRRT (See Types of Treatment) for NETs. Studies are looking at ways to improve the ability of tumor cells to attach to radiopeptides, how to use PRRT to eliminate very small traces of a NET, and ways to reduce other organs being exposed to radiation.
Palliative care/supportive care. Clinical trials are underway to find better ways of reducing symptoms and side effects of current treatments for a NET to improve comfort and quality of life for patients.
Abstract / Summary / Overview of Apoptosis.
Overview of apoptosis
•Programmed cell death
•Apoptosis is a form of programmed cell death, or “cellular suicide.”
•Apoptosis is different from necrosis, in which cells die due to injury.
•Apoptosis removes cells during development, eliminates potentially cancerous and virus-infected cells, and maintains balance in the body.
Why do cells undergo apoptosis?
- Basically, apoptosis is a general and convenient way to remove cells that should no longer be part of the organism.
- Some cells are abnormal and could hurt the rest of the organism if they survive, such as cells with viral infections or DNA damage.
- Apoptosis is part of development
- In many organisms, programmed cell death is a normal part of development.
The relationship between cancer cells and apoptosis
Apoptosis can eliminate infected or cancerous cells.
When a cell’s DNA is damaged, it will typically detect the damage and try to repair it.
If the damage is beyond repair, the cell will normally send itself into apoptosis, ensuring that it will not pass on its damaged DNA.
When cells have DNA damage but fail to undergo apoptosis, they may be on the road to cancer.
However, “successful” cancer cells successfully evade the process of apoptosis.
This allows them to divide out of control and accumulate mutations (changes in their DNA).
Apoptosis is key to immune function
Apoptosis also plays an essential role in the development and maintenance of a healthy immune system.
Where are the weaknesses and symptoms of cancer cells?
The symptoms of cancer cells are in the nucleus.
The nucleus controls the outer cytoplasm, cell composition, cell viability, etc.
DNA mutations also mutate in the nucleus.
Therefore, to treat cancer cells, we must first enter the nucleus.
Let the “regulatory cell gene” mechanism enter the nucleus to regulate
Are cancer cells aggressive?
After the action of Solamargine, the aggressiveness of cancer cells is alleviated.
So after using Solamargine, many patients feel that I am half better.
Although the tumor does not disappear quickly, patients feel that the degree of aggressiveness is reduced.
Extraordinary Solamargine (Role, Principle, Action, Mechanism, Function, Work).
Solamargine's major function mechanism:
When Solamargine enter,
Solamargine activates receptors that are turned off by cancer cells, allowing cancer cells to modulate again.
Solamargine modulates the anti-modulates genes of cancer cells, making cancer cells less resistant.
Reduced drug resistance
When cancer cells are less resistant to drugs, chemotherapy becomes more effective.
Solamargine modulates the mutated genes in cancer cells and then initiates cancer cell apoptosis to achieve anti-cancer effects.
Solamargine combined with which chemotherapy drugs are more effective in treating cancer cells?
Solamargine vs cancer
Solamargine vs cancer
The picture shows the death of cancer cells.
The black and black parts are cancer cell nuclei.
Even if the nucleus ruptures, the cancer cells will die.
The figure shows that cancer cells can cause death.
The figure shows that cancer cells can cause death.
The figure shows that the death of lung cancer cells is relatively slow, and it will not be obvious until eight hours later.
The figure shows that the death of liver cancer cells is very obvious, even more obvious in eight hours.
The graph shows that breast cancer cells die faster. It was obvious from the beginning that breast cancer is easy to treat, and patients with breast cancer need not worry.
Best Chemotherapy Adjuvant. (1+1>487%)
Effectively improve chemotherapy effect and treatment.
ANTI-CANCER
Patent protection in 32 nations.
A comparison study showing Solamargine vs. other therapeutic drugs with respect to lung cancer cells.
A comparison study showing Solamargine vs. other chemotherapeutic drugs with respect to breast cancer cells.
SR-T100 combination therapy with effective result against breast cancer cells.
Combination Therapy | Research results for lung cancer cells.
A. Chemotherapy (100μM), 16% of cancer cell apoptosis.
B. Alone SM (4.8μM), 28% of cancer cell apoptosis.
C. SM (4.80μM) + Chemotherapy (40μM), 66% of cancer cells apoptosis.
D. SM (4.80μM) + Chemotherapy (100μM), 78% of cancer cell apoptosis.
SM has a clearing effect better than Chemotherapy.
The combined treatment of Solamargine and Chemotherapy significantly increased the apoptosis of lung cancer cells.
SM (4.8μM) + Chemotherapy (40μM), increased from 16% to 66% (up to 4.125 times).
SM (4.8μM) + Chemotherapy (100μM), increased from 16% to 78% (up to 4.875 times).
Reorganized from: BBRC. Action of Solamargine on TNFs and drug-resistant human lung cancer cells 2004.
The best solution for cancer cells.